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Abstract

Vulvodynia is a chronic condition which affects an increasing number of women; it
presents currently an incidence that is higher than had previously been estimated. Regarding
pathogenesis, several (hormonal, infectious, inflammatory and psychological) factors have
been proposed, but vulvodynia etiology remains still unclear. This disorder is a
multifactorial condition with a significant impact on the patient’s quality of life, yet is
difficult to diagnose (an under-estimated/ under-recognized affection). Certain medical
investigations are required in order to exclude other diseases (the diagnosis of vulvodynia
being one of exclusion), but anamnesis and physical examination are essential steps in the
diagnosis.
Although many therapies have been proposed, both pharmacological and nonpharmacological, a standardized therapy has not yet been established/ generally accepted.
Accordingly, many therapeutic options have been studied with varying results. Vulvodynia
remains a challenging disease and a multidisciplinary approach is needed to achieve
satisfactory outcomes. Further studies are needed to completely understand its pathogenesis
and to develop a standardized treatment.
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vestibule (vestibulodynia) (4, 6). Recently, in April

Introduction
Vulvodynia (vulvar pain) is a chronic
condition affecting 9-12% of women and reported
in women aged 16 to 80 (1). Ethnic differences
have been observed, vulvodynia being more
frequently encountered in Caucasians than blacks

2015 a classification of chronic vulvar pain was
competed which indicates that the vulvar pain may
have a specific cause (inflammation, trauma,
neoplasm) or may be idiopathic, in which case the
term of vulvodynia should be used (4, 7).

(2). Most commonly patients complain of a burning Discussion
sensation in the vulvar region (3). Vulvodynia
represents an important public health issue; in the
United States, the cost of treating these patients

Pathogenesis
The pathogenic mechanism of vulvodynia is
not fully understood. Over time, several theories

varies between 31 and 72 billion dollars annually have been postulated, which have attributed roles to
(4).

hormonal,
For a long time vulvodynia was not clearly

defined.

In

1976

the

term

infectious/

inflammatory,

and

psychological factors in its pathogenesis (8).

“burning vulva  Role

of

infections.

Inflammatory

response

syndrome” was used, but in 2003, it was replaced developed as a consequence of genitourinary
with the term “vulvodynia” by the International infections may be involved in the occurrence of
Society for the Study of Vulvovaginal Disease- vulvodynia. For instance, in women with vaginal
ISSVD (5). According to the definition of the infection due to Trichomonas, pro-inflammatory
ISSVD, vulvodynia is a chronic pain localized in markers such as IL6, IL8 and TNF alpha were
the vulvar area which lasts more than 3 months identified. In another study, a group of women with
without a proven etiology. Several types of vulvodynia was compared with a group of healthy
vulvodynia are described: provoked vulvodynia women and it was observed that a significantly
(caused by direct touch, inserting a tampon, or higher percentage of those with vulvodynia were
sexual touch) localized especially by the vaginal infected with strains of human papilloma virus
vestibule,

unprovoked

vulvodynia

(occurring (HPV) (8). Some authors consider that vulvodynia

without touch or contact) and, mixed vulvodynia. It may occur due to hypersensitivity to various species
may be considered „generalized,” as when the of Candida (9). However no study has revealed a
symptoms involve the whole area of the vulva, or link between any infectious agent and the
localized to the clitoral area (clitorodynia) or to the development of vulvodynia.
142

Vulvodynia; an under-recognized disease

 Neuro-inflammatory hypothesis. In some cases of  Hormonal factors. Several authors have described
vulvodynia histopathological examination displayed an

association

between

the

use

of

oral

an inflammatory infiltrate consisting mainly of mast contraceptives and vulvodynia, but others have
cells; in other cases a reduced number of mast cells refuted this hypothesis (11). The study of Bazin et
was seen or the inflammatory infiltrate was not al. revealed that women who had used oral
identified. With respect to the mediators of contraceptives before age 17 had a higher risk of
developing vulvodynia. However the study has as a
inflammation, pro-inflammatory cytokines and
limitation a low number of women who did not use
vulvovaginal neurokine CGRP were revealed. Thus,
oral contraceptives (12).
the hypothesis of a neuro-inflammatory process
involved in the vulvodynia pathogenesis was  Psychological factors. In terms of psychological
suggested (10).
 Hyperinnervation. Many studies analysed the

factors, vulvodynia is identified more commonly in
women with an altered psychological status, those
with sleep disorders, with posttraumatic stress or

number of nerve fibers in the vulvar area and the
presence of hypersensitivity. A large number of
nerve endings acting as nociceptors were observed,
which may explain the allodynia experienced by
those women. A high sensitivity to different stimuli

suffering from chronic pain (2). Several studies
have highlighted that the women with vulvodynia
associate different conditions characterized by
chronic pain such as fibromyalgia, irritable bowel
syndrome,

interstitial

cystitis,

and

(tactile, thermic) was revealed especially in the temporomandibular joint disorders (13, 14).
patients with provoked vulvodynia (4). In addition,
Diagnosis
patients with vulvodynia have lower pain thresholds
than healthy women. Somatosensory changes were
detected mainly in the vestibular area (10).

The first symptoms may occur after the first
sexual contact or later, and in some cases in
childhood. Anamnesis and clinical examination are

 Muscles dysfunction. A role in the pathogenesis of

very important to differentiate between organic

vulvodynia has been attributed to pelvic floor chronic pain and vulvodynia. The anamnesis should
muscle dysfunction. Electromyographic studies include information about the patient’s sexual
have shown increased muscle tonus and impaired behaviour, local hygiene, and clothing. Many times
relaxation in these patients (10).

a correct diagnosis is achieved later, after many
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visits to different doctors; in some cases it may take and often interrupt the sexual acts due to
several years. Diagnosis of vulvodynia should dyspareunia (19).
remain a diagnosis of exclusion. Vulvodynia most
commonly occurs in women aged 20 to 40. A
higher incidence has been observed in Hispanics.
The pain varies in intensity and may be described as
a burning sensation or as a pruritus, or it may have
an irritative character. Erythema may be noticed
especially in the vestibular area and around the
Bartholin glands (15-17).

It was observed that remission of the
symptoms may occur in 10% of cases, even without
treatment and it seems to be related to the onset of
the disease. Therefore vulvodynia is primary when
the onset is at the time of sexual debut or first
tampon

insertion,

and

secondary

when

the

symptoms occur later. The remission occurs most
commonly in secondary vulvodynia, a fact that

In order to identify the sensitive vulvar area a suggests that a different etiopathogenic mechanism
cotton swab should be used. Commonly the higher may be involved. Analyzing tissue from the
sensitive area is identified in the posterior introitus involved areas, studies have revealed that in
and the posterior hymenal remnants. A thorough primary vulvodynia the density of nerve fibers is
genitourinary examination should be performed in higher and the degree of hyperplasia is greater (20).
order to rule out other conditions such as infections

The main differential diagnoses are allergic

or trauma. In addition, the patients should be vulvitis, chronic candida vulvovaginitis, lichen
referred to a gynaecologist and undergo a planus, lichen sclerosis, vaginismus and vulvar
colposcopy. An examination of the vaginal intraepithelial neoplasia (15).
secretion to rule out an infection should also be

Treatment

carried out (15, 18).
The first steps must focus on rules regarding
The most common form is localized provoked

hygiene and diet. The patient should avoid irritating

vulvodynia. Patients having this form report an products such as soaps and perfumes or alcoholintense and long-lasting pain, provoked by a touch, based creams and wear cotton clothes and use
in a certain region, while no pain is felt in other moisturizing creams. Studies have shown that a diet
regions. Patients state that the symptoms (pain, containing

less

oxalates

and

less

simple

burning) may last for several hours. In addition, carbohydrates may be useful. In addition, calcium
they present dysuria, difficulty in using tampons citrate may be administered due to its role in
144
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decreasing the oxalate deposits in the skin (1,21). In decrease

of

mast

many cases vulvodynia is not diagnosed and Corticosteroids

cells

may

be

degranulation
useful

if

they

(15).
are

appropriately treated (22). Since the etiology of the administered intralesionally; topical administration
disease is unknown and many mechanisms were did not prove effective (11).
supposed to be involved, the treatment is empirical
and includes various methods, pharmacological and
non-pharmacological. The approach to the patient
should be multidisciplinary (3, 23).

Other topical therapies reported in some
studies as effective are nitroglycerin, amitriptyline
2% in combination with baclofen 2% and topical
antifungal agents (24).

Topical treatment

Systemic treatment

Topical lidocaine 5% is the most common
drug administered in patients with vulvodynia.
Lidocaine through its anesthetic effect decreases
hypersensitivity. It is best applied in the evening or
before intercourse to relieve pain and discomfort.
Haefner

et

al.

have

revealed

significant

improvement of symptoms after 7 weeks of
treatment (24).

Tricyclic antidepressants, drugs used in
neuropathic pain, are often the first-line medication
in vulvodynia. Amitriptyline and desipramine are
most commonly used (21). However Leo et al. have
analysed the available studies on vulvodynia and
found no sufficient evidence to support their
administration

in

vulvodynia

(26).

Tricyclic

antidepressants act by blocking the reuptake of

Some authors have emphasized the efficacy of noradrenalin and serotonin. Serotonin inhibitors,
topical

capsaicin.

disadvantage

of

This

approach

causing

discomfort

has

the which are also administered in neuropathic pain,

on

the have been suggested as a therapeutic option, but

application area, being discontinued by patients in their effectiveness is still questionable, more useful
most cases (11). Estrogen cream may be applied being

selective

serotonin

and

norepinephrine

especially in premenopausal women, but studies reuptake inhibitors (9).
have shown a variable efficacy (16).
The

effectiveness

of

cromolyn

The
in

systemic

the anticonvulsant

medication

drugs,

also

gabapentin

includes
and

treatment of vulvodynia is controversial—in one carbamazepine, with success rate reported between
study results were no better than those of a placebo 50 and 82%. However further studies are needed to
group (25). Its mechanism of action is based on the demonstrate the efficacy of this drug class (24, 27).
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Surgery

Several studies have shown the beneficial role

In the case of localized pain, surgery may
represent a therapeutic option. Studies have
revealed that up to 80% of patients who undergo

of botulinum toxin in the treatment of vulvodynia.
Botulinum toxin inhibits the release of substance P
and glutamate from nociceptive neurons (29, 30).

vestibuloectomy report the remission of the disease The impact of vulvodynia on the quality of life
(21). Nevertheless this method should be reserved
for very serious cases (15). The recurrences are
common on the remaining vulvar tissue (21).

Vulvodynia has a significant impact on the
patient’s quality of life (31). Khandker et al. have
shown that patients with vulvodynia often exhibit

Other treatments

psychiatric

Psychological and psychosexual therapies
play an important role in the management of
patients with vulvodynia. Besides basic counseling
which may be performed by any physician and
consists of reassuring the patient that she has no any
underlying disease, cognitive behavioural therapy
may be used with significant benefits, according to

disorders

such

as

anxiety

and

depression; at the same time vulvodynia represents
a risk factor for developing such disorders. (32). It
has been observed that the disease has a major
social and emotional impact, limiting work-related
activities as well as leisure. In addition, these
women are sad and frustrated (33).
Patients with vulvodynia report a decrease in

some studies (3, 28). Psychosexual therapy may be sexual desire, in sexual satisfaction and frequency
useful in order to improve the sexual contact, of sexual acts. In addition, patients are more
requiring several sessions which are best carried out distressed about their body image (4, 34).
with the patient’s partner present (3).
Although

physical

therapy

is

not

a

standardized treatment, it may be effective. Physical

Conclusions
Vulvodynia is a disorder difficult to diagnose,

therapy includes active exercises for the pelvic with an incidence higher than previously thought. It
girdle and floor, soft tissue mobilization and joint is a multifactorial condition having a significant
manipulation, electrical stimulation, and bladder impact on the patient’s quality of life. The diagnosis
and bowel retraining (16, 24). It has been observed is one of exclusion, requiring further investigations.
that patients with vulvodynia have associated Many therapeutic options have been studied with
hypertonia of the pelvic floor (11).

varying results. Vulvodynia remains a challenging
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disease and a multidisciplinary team is needed to

2015 ISSVD, ISSWSH, and IPPS Consensus

achieve satisfactory outcomes. Further studies are

Terminology and Classification of Persistent

needed to completely understand its pathogenesis
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and to work out a standardized treatment.
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